Skip to main content
Premium Trial:

Request an Annual Quote

New York Gives Final Approval for Rosetta Genomics' miRview Lung Assay

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.

As a result, the company can offer the microRNA-based test for the differentiation of the four main subtypes of lung cancer in all 50 states. New York had given the test, launched in July 2011, conditional approval in June.

"This represents an important validation of our technology as many jurisdictions around the world recognize the rigor of review in the state of New York," Rosetta President and CEO Kenneth Berlin said in a statement. "With the introduction of targeted lung cancer therapies, along with new targeted drugs entering the clinical arena, accurate classification of lung cancer is becoming increasingly important to better assess efficacy profiles and to enhance treatment strategies."

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.